WO2010017500A3 - Anti-pancreatic cancer antibodies - Google Patents
Anti-pancreatic cancer antibodies Download PDFInfo
- Publication number
- WO2010017500A3 WO2010017500A3 PCT/US2009/053192 US2009053192W WO2010017500A3 WO 2010017500 A3 WO2010017500 A3 WO 2010017500A3 US 2009053192 W US2009053192 W US 2009053192W WO 2010017500 A3 WO2010017500 A3 WO 2010017500A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibodies
- pancreatic
- pancreatic cancer
- bind
- pam4
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009279503A AU2009279503B2 (en) | 2008-08-08 | 2009-08-07 | Anti-pancreatic cancer antibodies |
CA2731438A CA2731438C (en) | 2008-08-08 | 2009-08-07 | Anti-pancreatic cancer antibodies |
EP09805623.7A EP2331134A4 (en) | 2008-08-08 | 2009-08-07 | Anti-pancreatic cancer antibodies |
JP2011522288A JP5919604B2 (en) | 2008-08-08 | 2009-08-07 | Anti-pancreatic cancer antibody |
CN200980134258.8A CN102137681B (en) | 2008-08-08 | 2009-08-07 | Anti-pancreatic cancer antibodies |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8746308P | 2008-08-08 | 2008-08-08 | |
US61/087,463 | 2008-08-08 | ||
US12/343,655 US7993626B2 (en) | 2007-01-11 | 2008-12-24 | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
US12/343,655 | 2008-12-24 | ||
US14422709P | 2009-01-13 | 2009-01-13 | |
US61/144,227 | 2009-01-13 | ||
US12/418,877 US7906118B2 (en) | 2005-04-06 | 2009-04-06 | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology |
US12/418,877 | 2009-04-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010017500A2 WO2010017500A2 (en) | 2010-02-11 |
WO2010017500A3 true WO2010017500A3 (en) | 2010-04-22 |
Family
ID=41664221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/053192 WO2010017500A2 (en) | 2008-08-08 | 2009-08-07 | Anti-pancreatic cancer antibodies |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2331134A4 (en) |
JP (2) | JP5919604B2 (en) |
CN (1) | CN102137681B (en) |
AU (1) | AU2009279503B2 (en) |
CA (1) | CA2731438C (en) |
WO (1) | WO2010017500A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102485753A (en) * | 2010-12-03 | 2012-06-06 | 上海杰隆生物工程股份有限公司 | Human derived heavy chain variable region possessing human vascular endothelial growth factor binding activity |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8481041B2 (en) | 2005-04-06 | 2013-07-09 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy |
MX2012012736A (en) * | 2010-05-07 | 2013-02-26 | Hoffmann La Roche | Diagnostic method for the detection of cells ex vivo. |
EP2635300A4 (en) * | 2010-11-03 | 2014-04-02 | Ibc Pharmaceuticals Inc | Dock-and-lock (dnl) constructs for human immunodeficiency virus (hiv) therapy |
CA2814962A1 (en) * | 2010-12-02 | 2012-06-07 | Immunomedics, Inc. | In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents |
CN104244966B (en) * | 2011-11-15 | 2019-01-11 | 昆西生物科学有限公司 | Aequorin is for reducing neurotrosis caused by ischemic |
EP4035689A1 (en) | 2012-12-13 | 2022-08-03 | Immunomedics Inc. | Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity |
EP2981829A4 (en) * | 2013-04-01 | 2016-10-26 | Immunomedics Inc | Anti-mucin antibodies for early detection and treament of pancreatic cancer |
CA2899577C (en) * | 2013-04-03 | 2023-10-17 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
WO2014198995A1 (en) * | 2013-06-14 | 2014-12-18 | Universidad De Granada | Biomarkers for the diagnosis and the response to treatment of pancreatic cancer |
KR20150129932A (en) | 2014-05-12 | 2015-11-23 | 연세대학교 산학협력단 | A kit for pancreatic cancer diagnosis comprising complememt factor b-specific binding antibody |
EP3160499A4 (en) * | 2014-06-30 | 2018-03-14 | Immunomedics, Inc. | Antibodies reactive with an epitope located in the n-terminal region of muc5ac comprising cysteine-rich subdomain 2 (cys2) |
KR20160045547A (en) * | 2014-10-17 | 2016-04-27 | 에스케이텔레콤 주식회사 | Composition for diagnosing pancreatic cancer and method for diagnosing pancreatic cancer using the same |
CN104974988B (en) * | 2015-07-31 | 2016-08-24 | 南京麦科林生物医药科技有限公司 | Anti-pancreatic cancer monoclonal antibody and application thereof |
JP2021521106A (en) * | 2018-04-05 | 2021-08-26 | ターベダ セラピューティクス インコーポレイテッドTarveda Therapeutics,Inc. | HSP90 targeted conjugate and its formulation |
CN113056286A (en) * | 2018-09-10 | 2021-06-29 | 冷泉港实验室 | Methods for treating pancreatitis |
IL292133A (en) * | 2019-10-18 | 2022-06-01 | Nihon Mediphysics Co Ltd | Ri-labeled humanized antibody |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050014207A1 (en) * | 2002-06-14 | 2005-01-20 | Immunomedics, Inc. | Monoclonal antibody hPAM4 |
US20070044171A1 (en) * | 2000-12-14 | 2007-02-22 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
US20080171067A1 (en) * | 2007-01-17 | 2008-07-17 | Immunomedics, Inc. | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6357596A (en) * | 1986-08-29 | 1988-03-12 | Nisshin Flour Milling Co Ltd | Monoclonal antibody, production thereof and diagnosticum for hepatopathy composed of said antibody |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
AU2006232310B9 (en) * | 2005-04-06 | 2011-07-21 | Ibc Pharmaceuticals, Inc. | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
-
2009
- 2009-08-07 AU AU2009279503A patent/AU2009279503B2/en not_active Ceased
- 2009-08-07 CN CN200980134258.8A patent/CN102137681B/en not_active Expired - Fee Related
- 2009-08-07 JP JP2011522288A patent/JP5919604B2/en not_active Expired - Fee Related
- 2009-08-07 CA CA2731438A patent/CA2731438C/en not_active Expired - Fee Related
- 2009-08-07 WO PCT/US2009/053192 patent/WO2010017500A2/en active Application Filing
- 2009-08-07 EP EP09805623.7A patent/EP2331134A4/en not_active Withdrawn
-
2015
- 2015-01-21 JP JP2015009665A patent/JP2015110618A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070044171A1 (en) * | 2000-12-14 | 2007-02-22 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
US20050014207A1 (en) * | 2002-06-14 | 2005-01-20 | Immunomedics, Inc. | Monoclonal antibody hPAM4 |
US20080171067A1 (en) * | 2007-01-17 | 2008-07-17 | Immunomedics, Inc. | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites |
Non-Patent Citations (2)
Title |
---|
GOLD ET AL.: "A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma.", CANCER RES, vol. 68, no. 12, 15 June 2008 (2008-06-15), pages 4819 - 4826, XP002541923 * |
GOLD ET AL.: "PAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma.", CLIN CANCER RES, vol. 13, no. 24, 15 December 2007 (2007-12-15), pages 7380 - 7387, XP008144324 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102485753A (en) * | 2010-12-03 | 2012-06-06 | 上海杰隆生物工程股份有限公司 | Human derived heavy chain variable region possessing human vascular endothelial growth factor binding activity |
Also Published As
Publication number | Publication date |
---|---|
CA2731438A1 (en) | 2010-02-11 |
AU2009279503A1 (en) | 2010-02-11 |
JP2015110618A (en) | 2015-06-18 |
EP2331134A2 (en) | 2011-06-15 |
WO2010017500A2 (en) | 2010-02-11 |
CN102137681A (en) | 2011-07-27 |
JP2011530536A (en) | 2011-12-22 |
JP5919604B2 (en) | 2016-05-18 |
CA2731438C (en) | 2017-07-11 |
CN102137681B (en) | 2014-12-03 |
EP2331134A4 (en) | 2014-10-15 |
AU2009279503B2 (en) | 2014-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010017500A3 (en) | Anti-pancreatic cancer antibodies | |
PH12019500438A1 (en) | Anti-gcc antibody molecules and related compositions and methods | |
WO2009120905A3 (en) | Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof | |
WO2012112443A3 (en) | Anti-mucin antibodies for early detection and treatment of pancreatic cancer | |
MX355181B (en) | Human antibodies against human tissue factor. | |
SG153825A1 (en) | Multivalent immunoglobulin-based bioactive assemblies | |
IL242336A (en) | Method of detecting ca6 glycotope and use of a cytotoxic conjugate in the preparation of a medicament for treating cancer in a subject diagnosed with said cancer in accordance with said method | |
EA200970130A1 (en) | ANTAGONISTIC ANTIBODE FOR CANCER TREATMENT | |
WO2006099875A8 (en) | Antibodies against cd38 for treatment of multiple myeloma | |
WO2009083009A3 (en) | Monoclonal antibodies against cd32b | |
WO2005054273A3 (en) | Humanized antibodies against vascular endothelial growth factor | |
WO2005103081A3 (en) | Human monoclonal antibodies against cd20 | |
IN2012DN01663A (en) | ||
WO2008036449A3 (en) | Chemical antibodies for immunotherapy and imaging | |
WO2012012750A8 (en) | Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery | |
CA2740134C (en) | Formulations targeting igfbp7 for diagnosis and therapy of cancer | |
WO2011091113A3 (en) | Detection of early-stage pancreatic adenocarcinoma | |
GEP20135826B (en) | Novel antibodies used to treat cancer | |
EA200601405A1 (en) | HUMANIZED ANTIBODY | |
MX2021015974A (en) | Anti-tissue factor antibody-drug conjugates and related methods. | |
WO2008092002A3 (en) | Compositions and methods for treating and diagnosing pancreatic cancer | |
MX2023001776A (en) | Antibodies against ilt2 and use thereof. | |
WO2009148896A3 (en) | Anti-phospho-akt antibodies | |
WO2011040973A3 (en) | Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof | |
WO2004094612A3 (en) | Cancer specific monoclonal antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980134258.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09805623 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009279503 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2731438 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2011522288 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2009279503 Country of ref document: AU Date of ref document: 20090807 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 961/DELNP/2011 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009805623 Country of ref document: EP |